Legend Biotech Corporation (LEGN) News
Track canonical SquawkNews coverage tagged to LEGN, Legend Biotech Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 26 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Legend Biotech names Ingrid Zhang CEO
Legend Biotech (LEGN) appointed Ingrid Zhang as chief executive on Tuesday, ending a two-month search after former CEO Ying Huang resigned in July.
EQUITY | Sep 15, 2026, 11:40 PM UTC
M
Legend Biotech appoints Novartis veteran Ingrid Zhang as CEO
Legend Biotech (NASDAQ:LEGN) appointed longtime Novartis executive Ingrid Zhang as CEO, effective immediately.
EQUITY | Sep 15, 2026, 08:22 PM UTC
L
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech NASDAQ:LEGN on Tuesday appointed longtime Novartis BX:NOT executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy C
NEWS | Sep 15, 2026, 12:43 PM UTC
L
Legend Biotech appoints Ingrid Zhang as CEO
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
NEWS | Sep 15, 2026, 12:21 PM UTC
L
Legend Biotech: Zhang Most Recently Served as Chief Comml Officer for Novartis Intl >LEGN
Legend Biotech: Zhang Most Recently Served as Chief Comml Officer for Novartis Intl >LEGN
NEWS | Sep 15, 2026, 12:05 PM UTC
L
Legend Biotech: Zhang Succeeds Alan Bash, Who Has Served as Interim CEO Since July and Will Resume His Role as Pres, CARVYKTI >LEGN
Legend Biotech: Zhang Succeeds Alan Bash, Who Has Served as Interim CEO Since July and Will Resume His Role as Pres, CARVYKTI >LEGN
NEWS | Sep 15, 2026, 12:04 PM UTC
L
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search processBRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation NASDA
NEWS | Sep 15, 2026, 12:03 PM UTC
L
LEGN - Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
LEGN - Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
NEWS | Sep 15, 2026, 12:01 PM UTC
L
Legend Biotech Appoints Ingrid Zhang as CEO >LEGN
Legend Biotech Appoints Ingrid Zhang as CEO >LEGN
NEWS | Sep 15, 2026, 12:01 PM UTC
L
Legend Biotech Is Expected To Name Ingrid Zhang As Its New Chief Executive - WSJ
Legend Biotech Corporation NASDAQ:LEGN
NEWS | Sep 15, 2026, 11:35 AM UTC
L
Zhang Would Join From Post as Novartis International Commercial Chief — WSJ
Zhang Would Join From Post as Novartis International Commercial Chief — WSJ
NEWS | Sep 15, 2026, 11:30 AM UTC
L
Legend To Name Ingrid Zhang as Chief Executive, Sources Say — WSJ
Legend To Name Ingrid Zhang as Chief Executive, Sources Say — WSJ
NEWS | Sep 15, 2026, 11:30 AM UTC
L
Legend Biotech to present updated CARVYKTI long-term and real-world data at IMS meeting
Legend Biotech said data from CARTITUDE-2 and real-world evidence will be presented at the 23rd International Myeloma Society (IMS) Annual Meeting.
EQUITY | Sep 10, 2026, 12:04 PM UTC
L
LEGN - Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Socie
LEGN - Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
EQUITY | Sep 10, 2026, 12:01 PM UTC
L
HC Wainwright keeps LEGN price target at $65.00
HC Wainwright & Co. maintained its $65.00/share price target for Legend Biotech, according to Benzinga ratings actions (TradingView News).
EQUITY | Sep 04, 2026, 10:48 AM UTC
L
Legend Biotech CEO Alan Bash to speak at Morgan Stanley healthcare conference
Legend Biotech said interim CEO Alan Bash will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in N…
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
LEGN - Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
LEGN - Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
EQUITY | Sep 01, 2026, 12:00 PM UTC
M
ATAI, CRDF, GAP, LEGN, NVO Downgraded
ATAI, CRDF, GAP, LEGN, and NVO downgraded by various analysts
EQUITY | Aug 12, 2026, 10:47 AM UTC
M
LEGN Downgraded at Oppenheimer
LEGN downgraded at Oppenheimer
EQUITY | Aug 12, 2026, 10:05 AM UTC
L
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength o
EARNINGS | Aug 04, 2026, 10:04 AM UTC
L
LEGN new lows -13% after CEO headlines
LEGN new lows -13% after CEO headlines
EQUITY | Jul 27, 2026, 01:33 PM UTC
L
LEGN -4 premarket; Ying Huang steps down as CEO and board member, alan bash appointed interim CEO
LEGN -4 premarket; Ying Huang steps down as CEO and board member, alan bash appointed interim CEO
EQUITY | Jul 27, 2026, 10:24 AM UTC
L
LEGN - Legend Biotech Announces CEO Transition
LEGN - Legend Biotech Announces CEO Transition
EQUITY | Jul 27, 2026, 10:00 AM UTC
L
moves among today's downgrades ROL -3.2%, ACI -2.5%, FLYW -2.1%, LEGN -2.0%, HBAN -1.0%, TENB -0.4%, CAKE +0.0%, PAG +0.0%, INFY +2.9% moves
moves among today's downgrades ROL -3.2%, ACI -2.5%, FLYW -2.1%, LEGN -2.0%, HBAN -1.0%, TENB -0.4%, CAKE +0.0%, PAG +0.0%, INFY +2.9% moves among today's negative initiations - none
EQUITY | Jul 24, 2026, 01:40 PM UTC
L
LEGN Downgrade from Buy to Neutral W/$28.00 PT (from $49.00) at UBS
LEGN Downgrade from Buy to Neutral W/$28.00 PT (from $49.00) at UBS
EQUITY | Jul 24, 2026, 12:15 PM UTC
L
LEGN downgraded from Buy to Neutral W/ $28 PT (from $49) @ UBS
LEGN downgraded from Buy to Neutral W/ $28 PT (from $49) @ UBS
EQUITY | Jul 24, 2026, 11:32 AM UTC